论文部分内容阅读
目的探讨非诺贝特对早期糖尿病肾病患者的肾保护作用。方法将84例糖尿病肾病患者随机平均分为对照组和治疗组，对照组进行常规降糖降压治疗，治疗组在此基础上给予非诺贝特治疗，记录比较患者治疗前后血糖、血压、血肌酐(SCr)、血脂和微量白蛋白(mAlb)水平的变化以及核因子-κB (NF-κB)的活性。结果两组患者治疗后空腹血糖(FPG)、餐后2h血糖(2hPG)与治疗前相比较差异均有显著性(P 0.05)。两组治疗前后及组间 SCr 相相比较差异均无显著性(P>0.05)。对照组患者治疗前后血脂各项指标和 mAlb 水平无明显变化(P >0.05)；治疗组患者治疗后血脂各项指标和mAlb水平与治疗前比差异具有显著性(P 0.05)。对照组患者治疗前后 NF-κB的水平无明显变化(P >0.05)；而治疗组患者治疗后该水平较治疗前明显下降，且差异有显著性(P 0.05).There was no significant difference in blood lipids and microalbumin of control group between before and after treatment(P>0.05). There was significant difference in blood lipids and microalbumin of treatment group between before and after treatment (P<0.05).There was significant difference in blood lipids and microalbumin after treatment between treatment group and control group(P0.05).Compared with before treatment,NF-κB in treatment group after treatment was obviously de-creased,and there was significant difference(P<0.05).There was significant difference in NF-κB after treatment be-tween two groups(P<0.05).[Conclusion]Fenofibrate can obviously improve blood lipids and microalbumin,and de-crease the activity of NF-κB P6 5 in patients with early diabetic nephropathy.Therefore,it has renal protective effect.